Literature DB >> 16413272

Assays and properties of the ArfGAPs, AMAP1 and AMAP2, in Arf6 function.

Shigeru Hashimoto1, Ari Hashimoto, Atsuko Yamada, Yasuhito Onodera, Hisataka Sabe.   

Abstract

The GTPase-activating protein (GAP) domain for Arfs primarily consists of a zinc-finger structure, which is not present in known GAPs for the other Ras-superfamily GTPases. More than 20 genes have been found to encode proteins bearing the ArfGAP domain in the human genome: a number that is much larger than that of the Arf isoforms. Several Arf isoforms, such as Arf1 and Arf6, indeed have been shown to each employ multiple different ArfGAPs for their regulation and function. We have found that two ArfGAPs, namely AMAP1 and AMAP2, exhibit a novel biochemical property of directly and selectively binding to GTP-Arf6 without immediate GAPing activity, while they were previously shown to exhibit efficient catalytic GAPing activities to Arf isoforms except Arf6 in vitro. Such property of AMAPs appears to be important for AMAPs-mediated recruitment of auxiliary molecules, including paxillin, cortactin, amphiphysin, and intersectin, to sites of Arf6 activation. AMAPs thus appear to act as "effectors" rather than simple GAPs in some aspects of Arf6 function. This article presents methods and protocols developed for the functional characterization of AMAPs in Arf6 function. These methods may be applied to other types of ArfGAPs to further clarify the cellular functions of ArfGAPs as well as Arfs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16413272     DOI: 10.1016/S0076-6879(05)04021-8

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  8 in total

1.  Targeting AMAP1 and cortactin binding bearing an atypical src homology 3/proline interface for prevention of breast cancer invasion and metastasis.

Authors:  Shigeru Hashimoto; Mayumi Hirose; Ari Hashimoto; Masaki Morishige; Atsuko Yamada; Harumi Hosaka; Ken-ichi Akagi; Eiji Ogawa; Chitose Oneyama; Tsutomu Agatsuma; Masato Okada; Hidenori Kobayashi; Hiromi Wada; Hirofumi Nakano; Takahisa Ikegami; Atsushi Nakagawa; Hisataka Sabe
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-24       Impact factor: 11.205

2.  CIN85, a Cbl-interacting protein, is a component of AMAP1-mediated breast cancer invasion machinery.

Authors:  Jin-Min Nam; Yasuhito Onodera; Yuichi Mazaki; Hiroyuki Miyoshi; Shigeru Hashimoto; Hisataka Sabe
Journal:  EMBO J       Date:  2007-01-25       Impact factor: 11.598

3.  ArfGAPs: key regulators for receptor sorting.

Authors:  Yoko Shiba; Paul A Randazzo
Journal:  Receptors Clin Investig       Date:  2014-06-13

4.  The EGFR-GEP100-Arf6 pathway in breast cancer: Full invasiveness is not from the inside.

Authors:  Hisataka Sabe; Shigeru Hashimoto; Masaki Morishige; Ari Hashimoto; Eiji Ogawa
Journal:  Cell Adh Migr       Date:  2008-04-23       Impact factor: 3.405

5.  Rab5c promotes AMAP1-PRKD2 complex formation to enhance β1 integrin recycling in EGF-induced cancer invasion.

Authors:  Yasuhito Onodera; Jin-Min Nam; Ari Hashimoto; Jim C Norman; Hiroki Shirato; Shigeru Hashimoto; Hisataka Sabe
Journal:  J Cell Biol       Date:  2012-06-25       Impact factor: 10.539

6.  The Aryl-Hydrocarbon Receptor Protein Interaction Network (AHR-PIN) as Identified by Tandem Affinity Purification (TAP) and Mass Spectrometry.

Authors:  Dorothy M Tappenden; Hye Jin Hwang; Longlong Yang; Russell S Thomas; John J Lapres
Journal:  J Toxicol       Date:  2013-12-05

7.  CCL18 promotes breast cancer progression by exosomal miR-760 activation of ARF6/Src/PI3K/Akt pathway.

Authors:  Xiaojia Huang; Shengqing Lai; Fanli Qu; Zongyan Li; Xiaoyan Fu; Qian Li; Xiaofang Zhong; Chao Wang; Haiyan Li
Journal:  Mol Ther Oncolytics       Date:  2022-03-15       Impact factor: 7.200

Review 8.  The EGFR-GEP100-Arf6-AMAP1 signaling pathway specific to breast cancer invasion and metastasis.

Authors:  Hisataka Sabe; Shigeru Hashimoto; Masaki Morishige; Eiji Ogawa; Ari Hashimoto; Jin-Min Nam; Koichi Miura; Hajime Yano; Yasuhito Onodera
Journal:  Traffic       Date:  2009-04-21       Impact factor: 6.215

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.